Download May 23, 2016 07:00 ET Arm of I-SPY 2 TRIAL Investigating

May 23, 2016 07:00 ET
Arm of I-SPY 2 TRIAL Investigating Medivation's Talazoparib for Treatment of Breast Cancer Activated
Talazoparib Investigated in Neoadjuvant Setting in Patients with Newly Diagnosed, Locally Advanced
Breast Cancer
SAN FRANCISCO, CA--(Marketwired - May 23, 2016) - Medivation, Inc. (NASDAQ: MDVN) today
announced that the talazoparib-containing arm of the I-SPY 2 TRIAL (Investigation of Serial Studies to
Predict Your Therapeutic Response with Imaging And moLecular Analysis 2) has been activated. I-SPY 2,
sponsored by the QuantumLeap Healthcare Collaborative, combines a personalized medicine approach
and novel trial design to study investigational treatments in the neoadjuvant setting and is being
conducted by a consortium consisting of the U.S. Food and Drug Administration (FDA), the National
Cancer Institute (NCI), pharmaceutical and biotech companies, leading academic medical centers and
patient advocates.
"The I-SPY 2 TRIAL is designed to rapidly test promising agents to reduce the cost, time and number of
patients needed to bring new therapies to breast cancer patients who urgently need new treatment
options," said Laura J. Esserman, M.D., Principal Investigator of I-SPY 2 and Director of the Carol Franc
Buck Breast Care Center at the UCSF Helen Diller Family Comprehensive Cancer Center. "We are very
excited to initiate a new trial arm of talazoparib that is designed to optimize our understanding of this
investigational drug and avoid some of the complications of paclitaxel, which is part of the current
standard treatment. We are building on what we know of the PARP-inhibitor drug class and looking for
ways to maximize benefit and minimize toxicity, which is what all women want."
The I-SPY 2 TRIAL is a Phase II, randomized, controlled, multi-center trial for women with newly
diagnosed, locally advanced breast cancer (Stage II/III). The trial employs an adaptive design, matching
experimental therapies with patients based on the use of biomarkers, investigating whether new
therapies can be added to standard chemotherapy or whether they may replace certain components of
standard chemotherapy in the neoadjuvant setting. Therapies that are found effective can move onto a
more focused Phase III registration trial.
"We are delighted that the combination of talazoparib and irinotecan was chosen to be evaluated in this
innovative trial design seeking to replace components of standard chemotherapy with more targeted,
potentially less toxic agents," said Amy Peterson, M.D., Vice President, Clinical Research, Medivation.
"This trial will allow us to gather important information about the activity and tolerability of this
combination in a breast cancer patient population that goes beyond germline BRCA1/2 carriers and is an
example of Medivation's commitment to rapidly and efficiently bring impactful medicines to patients in
need."
The talazoparib arm of the I-SPY 2 TRIAL will enroll up to 75 patients with HER-2 negative breast cancer.
Patients will be treated initially with talazoparib daily and irinotecan every two weeks for 12 weeks
followed by treatment with doxorubicin and cyclophosphamide. Patients in the comparator arm will
receive standard paclitaxel therapy followed by doxorubicin and cyclophosphamide treatment. The
primary endpoint of the trial is pathologic complete response (pCR), defined as the absence of clinical
and pathological evidence of invasive tumor in breast or lymph nodes.
For more information about the I-SPY 2 TRIAL, visit www.clinicaltrials.gov, trial identifier NCT01042379.
About Talazoparib
Talazoparib is a potent and specific inhibitor of PARP 1 and 2(i) that is being developed by Medivation for
the treatment of selected solid tumors. In pre-clinical studies, talazoparib has shown single-agent antitumor activity, as well as synergy in combination with lowered doses of DNA-damaging agents, due to its
dual mechanisms of cytotoxicity, PARP trapping, and inhibition of PARP enzyme activity. Trapping of
PARP on DNA impairs DNA replication resulting in tumor cell death. Talazoparib currently is in Phase III
development for patients with locally advanced and/or metastatic breast cancer who harbor a germline
BRCA1/2 mutation.
About Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of
medically innovative therapies to treat serious diseases for which there are limited treatment options.
Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and
their families. For more information, please visit http://www.medivation.com
Forward-Looking Statement
This press release contains forward-looking statements, which are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks
and uncertainties which may cause actual results to differ significantly from those expressed or implied
herein. Factors that could cause or contribute to such differences include, but are not limited to, adverse
results in investigator-sponsored clinical trials that could cause delay or discontinuation of Medivation's
ongoing or planned development activities for talazoparib; the inherent uncertainty associated with
pharmaceutical product development, clinical trials and the regulatory approval process; changes in
healthcare and pharmaceutical laws and regulations and reimbursement practices; and other risks
detailed in Medivation's filings with the Securities and Exchange Commission, or SEC, including its
quarterly report on Form 10-Q for the quarter ended March 31, 2016, which was filed on May 5, 2016.
You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of
the date of this press release. Medivation disclaims any obligation or undertaking to update, supplement
or revise any forward-looking statements contained in this press release.
(i)
Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, et al. BMN673, a novel and highly potent PARP1/2
inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res. 2013;19:500315.